Collegium Pharmaceutical, Inc.
Simbolis: COLL
NASDAQ
37.51
USDRinkos kaina šiandien
25.1608
P/E santykis
1.5484
PEG koeficientas
1.20B
MRK kapitalizacija
- 0.00%
DIV pajamingumas
Collegium Pharmaceutical, Inc. (COLL) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 1210.06 | 310.5 | 173.7 | 186.4 | |||||||||||
balance-sheet.row.short-term-investments | 159.35 | 71.6 | 0 | 0 | |||||||||||
balance-sheet.row.net-receivables | 707.98 | 179.5 | 183.1 | 105.8 | |||||||||||
balance-sheet.row.inventory | 125.38 | 32.3 | 46.5 | 17.4 | |||||||||||
balance-sheet.row.other-current-assets | 51.76 | 0.1 | 16.7 | 0 | |||||||||||
balance-sheet.row.total-current-assets | 2110.28 | 537.6 | 420 | 315.5 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 94.93 | 22 | 26.4 | 27.1 | |||||||||||
balance-sheet.row.goodwill | 535.43 | 133.9 | 133.7 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 1900.47 | 421.7 | 567.5 | 268.7 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 2435.9 | 555.6 | 701.2 | 268.7 | |||||||||||
balance-sheet.row.long-term-investments | 3.52 | 1 | 2.5 | 2.5 | |||||||||||
balance-sheet.row.tax-assets | 100.57 | 26.3 | 23.9 | 78 | |||||||||||
balance-sheet.row.other-non-current-assets | 3.89 | 0.8 | 0.1 | 0.1 | |||||||||||
balance-sheet.row.total-non-current-assets | 2638.81 | 605.7 | 754.1 | 376.5 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 4749.1 | 1143.3 | 1174.1 | 692.1 | |||||||||||
balance-sheet.row.account-payables | 17.76 | 8.7 | 39.6 | 33.4 | |||||||||||
balance-sheet.row.short-term-debt | 737.3 | 184.3 | 163.6 | 49.2 | |||||||||||
balance-sheet.row.tax-payables | 21.59 | 7.1 | 4.4 | 3.2 | |||||||||||
balance-sheet.row.long-term-debt-total | 2223.97 | 490 | 709.2 | 258.8 | |||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 1015.23 | 264.9 | 66.9 | 147.8 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 2223.97 | 490 | 709.2 | 258.8 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 29.98 | 7.1 | 8.2 | 8.8 | |||||||||||
balance-sheet.row.total-liab | 3994.26 | 947.9 | 979.3 | 489.1 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0.15 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.retained-earnings | -1082.85 | -233.2 | -281.3 | -256.3 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -0.08 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 1837.62 | 428.6 | 476.1 | 459.2 | |||||||||||
balance-sheet.row.total-stockholders-equity | 754.84 | 195.4 | 194.8 | 202.9 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 4749.1 | 1143.3 | 1174.1 | 692.1 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | 754.84 | 195.4 | 194.8 | 202.9 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 4749.1 | - | - | - | |||||||||||
Total Investments | 161.9 | 71.6 | 2.5 | 2.5 | |||||||||||
balance-sheet.row.total-debt | 2961.26 | 674.3 | 872.8 | 258.8 | |||||||||||
balance-sheet.row.net-debt | 1910.56 | 435.3 | 699.1 | 72.3 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 48.16 | 48.2 | -25 | 71.5 | |||||||||||
cash-flows.row.depreciation-and-amortization | 149.26 | 149.3 | 138.9 | 68.9 | |||||||||||
cash-flows.row.deferred-income-tax | -2.15 | -2.2 | -8.4 | -78 | |||||||||||
cash-flows.row.stock-based-compensation | 27.14 | 27.1 | 22.9 | 24.3 | |||||||||||
cash-flows.row.change-in-working-capital | 21.73 | 21.7 | -12.7 | 13.5 | |||||||||||
cash-flows.row.account-receivables | 3.59 | 3.6 | -21.8 | -22.5 | |||||||||||
cash-flows.row.inventory | 14.17 | 14.2 | 48.3 | -2.3 | |||||||||||
cash-flows.row.account-payables | 5.06 | 5.1 | -0.7 | -5.8 | |||||||||||
cash-flows.row.other-working-capital | 23.77 | -1.1 | -38.5 | 44.1 | |||||||||||
cash-flows.row.other-non-cash-items | 30.62 | 30.6 | 8.5 | 3.4 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 274.75 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.46 | -0.5 | -1.6 | -1.9 | |||||||||||
cash-flows.row.acquisitions-net | -41.66 | 0 | -572.1 | 0 | |||||||||||
cash-flows.row.purchases-of-investments | -92.35 | -92.4 | 0 | 0 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 22 | 22 | 0 | 0 | |||||||||||
cash-flows.row.other-investing-activites | 41.66 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -70.81 | -70.8 | -573.7 | -1.9 | |||||||||||
cash-flows.row.debt-repayment | -301.14 | -301.1 | -75 | -50 | |||||||||||
cash-flows.row.common-stock-issued | 1.84 | 9.1 | 11.8 | 12.7 | |||||||||||
cash-flows.row.common-stock-repurchased | -75.05 | -75 | -14.1 | -47.9 | |||||||||||
cash-flows.row.dividends-paid | -57.53 | -9.1 | 0 | -12.7 | |||||||||||
cash-flows.row.other-financing-activites | 291.69 | 236 | 514 | 8.6 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -140.18 | -140.2 | 436.7 | -89.3 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | 63.76 | 63.8 | -12.7 | 12.3 | |||||||||||
cash-flows.row.cash-at-end-of-period | 1056.4 | 240 | 176.2 | 189 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 992.64 | 176.2 | 189 | 176.7 | |||||||||||
cash-flows.row.operating-cash-flow | 274.75 | 274.7 | 124.2 | 103.6 | |||||||||||
cash-flows.row.capital-expenditure | -0.46 | -0.5 | -1.6 | -1.9 | |||||||||||
cash-flows.row.free-cash-flow | 274.29 | 274.3 | 122.6 | 101.6 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 566.77 | 566.8 | 463.9 | 276.9 | |||||||||||
income-statement-row.row.cost-of-revenue | 240.6 | 240.6 | 254.4 | 126.3 | |||||||||||
income-statement-row.row.gross-profit | 326.17 | 326.2 | 209.5 | 150.6 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.operating-expenses | 159.21 | 159.2 | 176.2 | 128.4 | |||||||||||
income-statement-row.row.cost-and-expenses | 399.81 | 399.8 | 430.6 | 254.7 | |||||||||||
income-statement-row.row.interest-income | 15.62 | 15.6 | 1 | 0 | |||||||||||
income-statement-row.row.interest-expense | 83.34 | 83.3 | 63.2 | 21 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | -91.23 | -23.5 | 75.7 | 43.3 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.total-operating-expenses | -91.23 | -23.5 | 75.7 | 43.3 | |||||||||||
income-statement-row.row.interest-expense | 83.34 | 83.3 | 63.2 | 21 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 152 | 149.3 | 138.9 | 68.9 | |||||||||||
income-statement-row.row.ebitda-caps | 331.83 | - | - | - | |||||||||||
income-statement-row.row.operating-income | 166.96 | 167 | -104.6 | -46.7 | |||||||||||
income-statement-row.row.income-before-tax | 75.73 | 75.7 | -28.8 | -3.4 | |||||||||||
income-statement-row.row.income-tax-expense | 27.58 | 27.6 | -3.8 | -74.9 | |||||||||||
income-statement-row.row.net-income | 48.16 | 48.2 | -25 | 71.5 |
Dažnai užduodami klausimai
Kas yra Collegium Pharmaceutical, Inc. (COLL) bendras turtas?
Collegium Pharmaceutical, Inc. (COLL) bendras turtas yra 1143308000.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra 286454000.000.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.575.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra 8.492.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra 0.085.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra 0.295.
Kas yra Collegium Pharmaceutical, Inc. (COLL) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra 48155000.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 674283000.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 159208000.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 238947000.000.